NASDAQ:CASI - CASI Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.64 -0.16 (-4.21 %) (As of 01/20/2019 12:09 PM ET)Previous Close$3.64Today's Range$3.62 - $3.8352-Week Range$2.73 - $8.89Volume236,779 shsAverage Volume398,104 shsMarket Capitalization$346.84 millionP/E RatioN/ADividend YieldN/ABeta1.41 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma and triple-negative breast cancer. The company's late-stage clinical drug candidates, including EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma; MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; and ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma. It also offers a portfolio of 25 U.S. food and drug administration-approved abbreviated new drug applications and 1 abbreviated new drug applications. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland. Receive CASI News and Ratings via Email Sign-up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CASI Previous Symbol CUSIPN/A Webwww.casipharmaceuticals.com Phone240-864-2600Debt Debt-to-Equity RatioN/A Current Ratio14.65 Quick Ratio14.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book6.62Profitability EPS (Most Recent Fiscal Year)($0.18) Net Income$-10,770,000.00 Net MarginsN/A Return on Equity-30.70% Return on Assets-28.69%Miscellaneous Employees51 Outstanding Shares95,290,000Market Cap$346.84 million OptionableNot Optionable CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions What is CASI Pharmaceuticals' stock symbol? CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI." How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals Inc (NASDAQ:CASI) posted its earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.06. View CASI Pharmaceuticals' Earnings History. When is CASI Pharmaceuticals' next earnings date? CASI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for CASI Pharmaceuticals. What price target have analysts set for CASI? 1 brokers have issued 12 month target prices for CASI Pharmaceuticals' shares. Their predictions range from $7.00 to $7.00. On average, they expect CASI Pharmaceuticals' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price. View Analyst Price Targets for CASI Pharmaceuticals. What is the consensus analysts' recommendation for CASI Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CASI Pharmaceuticals. Has CASI Pharmaceuticals been receiving favorable news coverage? News articles about CASI stock have trended extremely positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CASI Pharmaceuticals earned a news impact score of 4.1 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. Who are some of CASI Pharmaceuticals' key competitors? Some companies that are related to CASI Pharmaceuticals include Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO), Iovance Biotherapeutics (IOVA), Orchard Therapeutics (ORTX), Rubius Therapeutics (RUBY), Audentes Therapeutics (BOLD), Fate Therapeutics (FATE), BioCryst Pharmaceuticals (BCRX), Solid Biosciences (SLDB), Coherus Biosciences (CHRS), Novavax (NVAX), Vericel (VCEL) and Acorda Therapeutics (ACOR). Who are CASI Pharmaceuticals' key executives? CASI Pharmaceuticals' management team includes the folowing people: Dr. Wei-Wu He, Exec. Chairman (Age 54)Dr. Ken Keyong Ren, CEO & Director (Age 60)Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 49)Dr. Alexander A. Zukiwski, Chief Medical Officer (Age 62)Mr. George Chi, Chief Financial Officer Who are CASI Pharmaceuticals' major shareholders? CASI Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Meeder Asset Management Inc. (0.01%). Company insiders that own CASI Pharmaceuticals stock include China Growth Fund Idg-Accel II, Spectrum Pharmaceuticals Inc and Wei-Wu He. View Institutional Ownership Trends for CASI Pharmaceuticals. Which major investors are buying CASI Pharmaceuticals stock? CASI stock was bought by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include China Growth Fund Idg-Accel II, Spectrum Pharmaceuticals Inc and Wei-Wu He. View Insider Buying and Selling for CASI Pharmaceuticals. How do I buy shares of CASI Pharmaceuticals? Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CASI Pharmaceuticals' stock price today? One share of CASI stock can currently be purchased for approximately $3.64. How big of a company is CASI Pharmaceuticals? CASI Pharmaceuticals has a market capitalization of $346.84 million. The biotechnology company earns $-10,770,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. CASI Pharmaceuticals employs 51 workers across the globe. What is CASI Pharmaceuticals' official website? The official website for CASI Pharmaceuticals is http://www.casipharmaceuticals.com. How can I contact CASI Pharmaceuticals? CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected] MarketBeat Community Rating for CASI Pharmaceuticals (NASDAQ CASI)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 122 (Vote Outperform)Underperform Votes: 113 (Vote Underperform)Total Votes: 235MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote "Outperform" if you believe CASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2019 by MarketBeat.com StaffFeatured Article: Why is the price-sales ratio important?